Navigation Links
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Date:4/22/2008

SPIRIT III Results Demonstrate Superior Reduction in In-Segment Late Loss, Non-Inferiority in Target Vessel Failure and Low Rates of MACE with XIENCE

V Compared to TAXUS

ABBOTT PARK, Ill., April 22 /PRNewswire-FirstCall/ -- A study published in today's Journal of the American Medical Association (JAMA) demonstrated that use of Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent System in patients with coronary artery disease resulted in a significant 50 percent reduction in vessel renarrowing (in-segment late loss) at eight months, non-inferior rates of target vessel failure (TVF) at nine months, and an observed 42 percent reduction in major adverse cardiac events (MACE) at one year compared to the TAXUS(R) Paclitaxel-Eluting Coronary Stent System. The SPIRIT III study is a 1,002-patient, prospective, multi-center, randomized clinical trial designed to evaluate the safety and efficacy of the XIENCE V stent system compared to the TAXUS stent system.

"SPIRIT III is the first large-scale clinical trial to show that patients have a lower risk of experiencing a heart attack, cardiac death or re-treatment when treated with a new stent, XIENCE V, compared to the most widely used drug eluting stent TAXUS," said Gregg W. Stone, M.D., of the Columbia University Medical Center; chairman, Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III clinical trial. "With a significant reduction in angiographic in-segment late loss, non-inferiority in target vessel failure and a clinical advantage in the composite rate of MACE compared to TAXUS, XIENCE V represents an important advance in improving the lives of patients with coronary artery disease."

The SPIRIT III clinical trial demonstrated the following key results for XIENCE V:
-- Statistical superiority to TAXUS on the study's primary endpoint of

in-segment late loss at eight months. XIENCE V demonstrated a


'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
2. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
3. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
4. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
5. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
8. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
9. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/27/2008)...ec. 23 Warner Chilcott L...of its subsidiaries and Mayne Pharma International...., have filed lawsuits against each of Mutual Phar...euticals Inc. ("Mylan") and Impax Laboratories, In...ct of New Jersey for infringement of Mayne,s U.S. ...
(Date:12/17/2008)...n development and validation of non-animal alterna...17 MatTek Corporation today announ...ESAC) endorsed the scientific validity of the Modi...ember meeting. ESAC concluded that the Modified E... for the prediction of skin irritating and non-irr...
(Date:12/17/2008)... PEAK Surgical, Inc., a medical,de...ction system based on a,proprietary technology, a...stration (FDA) has granted the company 510(k) clea...tting and coagulation of soft tissue during,plast... gynecologic,orthopedic, arthroscopic, spinal an...
(Date:12/17/2008)...e, December 17 NicOx,S....tive results of a,pre-specified pooled analysis o...e 301, 302 and 303 pivotal phase 3 studies for nap...ificant reduction in systolic and diastolic blood,...g bid over the whole 13 week,period (p<0.001 f...
Breaking Medicine Technology:Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3EpiDerm's Skin Irritation Test Fully Validated in European Union 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 2NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 3NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 5June GEOSPHERE media highlights 3472 1June GEOSPHERE media highlights 3472 2June GEOSPHERE media highlights 3472 3June GEOSPHERE media highlights 3472 4Inflammation depression and antidepressant response 3A Common mechanisms 20582 1OHSU Cancer Institute researchers find many stomach cancer patients are not gertting best therapy 20578 1OHSU Cancer Institute researchers find many stomach cancer patients are not gertting best therapy 20578 2Certain Tests in ERs Raise Cancer Risk for Some 20575 1Certain Tests in ERs Raise Cancer Risk for Some 20575 2Certain Tests in ERs Raise Cancer Risk for Some 20575 3Certain Tests in ERs Raise Cancer Risk for Some 20575 4
(Date:1/8/2009)..., First Announced Acquisition in 2009 Continues G... IPC The Hospitalist Com...ospitalist physician group practice company, annou...actice of Midwest Acute Care Consultants, Inc. (MA...ents continued expansion in the St. Louis market, ...
(Date:1/8/2009)..., BETHESDA, Md., Jan. 8 /PRNewswire-Asia/ -- ...HDX" or "the Company"), a leading independent Amer...services in the People,s Republic,of China, today...BS Greater,China Conference, to be held in Shangh... Greater China Conference will be held at the Pudo...
(Date:1/8/2009)..., ROCKVILLE, Md., Jan. 8 /PRNewswire-USNewswire/ ...ctives, advice and guidance on drugs, biological p...althcare Research and Quality,s Centers for Educat...lly sponsored network of more than a dozen leading...mer Health Advisory Information Network ( CHAIN ) ...
(Date:1/8/2009)..., FRAZER, Pa., Jan. 8 ...that Frank Baldino, Jr., Ph.D., Chairman and CEO w...nce, to be held on January 13, 2009 in San Francis...p.m. Eastern Time). The presentation will be webca...ompany,s website. , , The webcast will be arch...
Breaking Medicine News(10 mins):Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3
...ic and geographic data of the H5N1 avian flu virus...//They found that multiple strains of the virus or... they identified many of the migration routes thro...y and internationally. By knowing where H5N1 stra...
...ons of brain function in the field of conducting t...reparing to move when a traffic light turns green.... of psychology at the Georgia Institute of Technol... they conducted MRI brain scans of their subjects ...
...daily may have the potential to reverse impairment... to a first-of-its-kind study published in the Jou...d in the study was rich in flavanols, naturally-oc...ocoa prior to their destruction during the typical...
...netic roots of the most common form of amyotrophic...e newly identified 34 unique variations in the hum...ALS. The 34 so-called single nucleotide polymorp...e genes predisposing people to the noninherited fo...
Other Medicine News:Health News:UCI Scientists Reconstruct Migration of Avian Flu Virus 2Health News:Same Areas of the Brain Prepare for and Respond to a Stimulus, Say Experts 2Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 2Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 3Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 4Health News:Gene Hunters at Johns Hopkins Close In On Lou Gehrig's Disease 2
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
Medicine Products: